Jiangsu Furui Pharmaceuticals

Jiangsu Furui Pharmaceuticals is a Chinese pharmaceutical company and a key subsidiary of the Jiangsu Alpha Group, specializing in the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and finished drug products. The company is widely recognized for its expertise in cardiovascular medicine, particularly in the production of statins such as atorvastatin and rosuvastatin, where it holds a significant global market share. Its innovative pipeline is led by sulcardine sulfate (HBI-3000), a multi-ion channel blocker in Phase 2 development for the treatment of arrhythmias, including atrial fibrillation. Jiangsu Furui operates advanced manufacturing facilities in Suqian and Xiangtan and maintains a dedicated R&D center in Shanghai. The company leverages strategic partnerships with the Shanghai Institute of Materia Medica and HUYA Bioscience International to advance its therapeutic candidates in both domestic and international markets. It also provides contract development and manufacturing (CDMO) services, utilizing technologies like continuous flow micro-channel reactors for efficient chemical synthesis.